Venous thromboembolism is frequent in chronic myeloproliferative neoplasms (MPNs). The current strategy for its management includes cytoreductive therapy and antithrombotic prophylaxis, but many issues remain uncertain. In this review, the risk factors and prevention of recurrences are discussed.
Curr Opin Hematol